BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19173838)

  • 1. [Doxorubicin and etoposide-besed combination chemotherapy regimen for peripheral T-cell lymphoma].
    Zheng W; Zhu J; Xie Y
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):875-6. PubMed ID: 19173838
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
    Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
    Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methotrexate and prednisone.
    Gerlando Q; Barbera V; Ammatuna E; Franco V; Florena AM; Mariani G
    Haematologica; 2000 Aug; 85(8):880-1. PubMed ID: 10942945
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
    Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
    Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
    Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
    Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
    Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
    Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
    Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
    Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-cancer agents. Unique protocol looks promising for lymphoma.
    TreatmentUpdate; 2003; 15(4):5-7. PubMed ID: 17216853
    [No Abstract]   [Full Text] [Related]  

  • 13. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
    Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
    Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensive chemotherapy with cisplatin, vincristine, doxorubicin and etoposide against lung cancer: a pilot study.
    Yanagawa H; Bando H; Takishita Y
    Anticancer Res; 1995; 15(2):613-6. PubMed ID: 7539241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
    Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma.
    Alaibac M; Berti E; Pigozzi B; Chiarion V; Aversa S; Marino F; Peserico A
    J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S121-3. PubMed ID: 15858508
    [No Abstract]   [Full Text] [Related]  

  • 19. [CAMBO-VIP for advanced diffuse large cell lymphoma (LSG classification)--a long-term follow-up study].
    Okamoto M; Maruyama F; Tsuzuki M; Nomura T; Miyazaki H; Wakita M; Kojima H; Sobue R; Matsui T; Ino T
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):67-73. PubMed ID: 7507314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma.
    Mishima Y; Nagasaki E; Terui Y; Irie T; Takahashi S; Ito Y; Oguchi M; Kawabata K; Kamata S; Hatake K
    Cancer; 2004 Sep; 101(6):1437-44. PubMed ID: 15368332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.